Form 4: Cytosorbents CMO Granted Equity Awards

Cytosorbents' Chief Medical Officer, Efthymios Deliargyris, received 70,000 restricted stock units and 95,000 stock options, aligning executive incentives with company performance.

Summary

• Chief Medical Officer Efthymios Deliargyris was granted 70,000 Restricted Stock Units (RSUs) and 95,000 stock options on August 8, 2025.
• The 70,000 RSUs vest in equal parts on the first and second-year anniversaries of the grant date, contingent on continued service.
• The 95,000 stock options have an exercise price of $1 and vest over three years: 50% on the first anniversary, 25% on the second, and 25% on the third, also subject to continued service. These options expire on August 8, 2035.
• Following these transactions, Deliargyris beneficially owns 473,025 shares of Common Stock and 95,000 stock options.
• The Common Stock ownership includes 120,000 RSUs from April 9, 2020, and 55,000 RSUs from August 10, 2022, both vesting upon a "Change In Control."
• It also includes 30,500 unvested RSUs from a 61,000 RSU grant on April 2, 2024, which vest over two years, and 197,525 directly owned shares of Common Stock.

Sentiment

Score: 7

Explanation: The grant of equity awards to a key executive is generally a positive signal, indicating management alignment with shareholder interests and a commitment to long-term value creation. It's a standard compensation practice.

Positives

• Granting of equity awards (RSUs and stock options) to the Chief Medical Officer aligns executive incentives with long-term shareholder value.
• The vesting schedules for both RSUs (2 years) and stock options (3 years) encourage long-term commitment and performance from a key executive.

Risks

• Vesting of RSUs and stock options is subject to the reporting person's continued service, meaning the awards could be forfeited if employment ceases before vesting.
• The value of the stock options is dependent on the future stock price exceeding the $1 exercise price.
• Some RSUs only vest upon a "Change In Control," introducing a contingency that may not materialize.

Future Outlook

The equity grants are designed to incentivize the Chief Medical Officer's long-term commitment and performance, aligning with the company's future strategic objectives and shareholder value creation.

Management Comments

• The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.
• These shares represent restricted stock units ("RSUs") which shall vest in equal parts at the first and second year anniversaries of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

Industry Context

This Form 4 filing reflects a standard practice in the biotechnology and medical device industry where executive compensation packages often include equity components like RSUs and stock options to attract, retain, and motivate key talent, linking their financial success to the company's long-term performance.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive incentives with company performance and long-term value creation.
• Employees: May signal stability in executive leadership and a commitment to retaining key talent.

Next Steps

• Continued service of Efthymios Deliargyris to ensure vesting of RSUs and stock options.
• Future reporting of beneficial ownership changes via subsequent Form 4 filings.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a key executive, which is a standard compensation practice aimed at aligning management incentives with long-term shareholder value. While positive for governance and executive retention, it does not provide new fundamental information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment stance. Investors should continue to monitor broader company performance and market conditions.

Keywords

Cytosorbents, CTSO, SEC Form 4, Insider Trading, Equity Grant, Restricted Stock Units, RSUs, Stock Options, Executive Compensation, Efthymios Deliargyris, Chief Medical Officer